Treatment Technology Research

Treatment Technology Research (TTR) is a clinical-stage Japanese biotechnology company dedicated to the development of innovative oncology therapeutics. Spun out from the National Cancer Center Japan, the company focuses on commercializing high-potential research discoveries, particularly in the field of DNA repair and cancer metabolism. Its lead candidate, TTR-001, is a first-in-class small molecule inhibitor of MTH1 (MutT homolog 1) designed to induce cancer cell death by preventing the detoxification of oxidized nucleotides. TTR operates through a collaborative model, leveraging the clinical and research infrastructure of the National Cancer Center to accelerate drug development. The company aims to bridge the gap between basic scientific research and effective clinical treatments for patients with high unmet medical needs.